#MyelomaMonday

Did you know? Myeloma is the 3rd most common blood cancer in Europe. During 2022, there were over 50,000 new diagnoses reported alone.

#BloodCancer #MyelomaAwareness #EarlyDiagnosis #MyelomaPatientsEurope

Every approved myeloma treatment started as a clinical trial. Clinical trials need diverse participants from across Europe to ensure treatments work for everyone. 

Discover our clinical trial navigator. https://f.mtr.cool/mtcrmjuonf

#MyelomaMonday

#MyelomaMonday

MRD testing can detect a single cancer cell among one million — helping doctors see how well your treatment is working.

Learn what MRD means for your care 👇
mpeurope.org/what-we-do/educational-resources/qas/minimal-residual-disease-mrd/

Yesterday was International Women's Day — today we recognise women living with myeloma and those caring for loved ones with the condition. To every woman in our myeloma community — thank you. 💙

#MyelomaMonday #MyelomaAwarenessMonth #InternationalWomensDay

#MyelomaMonday

Searching for clinical trials doesn't have to be hard. Our short video walks you through how to use the Myeloma and AL Amyloidosis Clinical Trial Navigator step by step. https://f.mtr.cool/ntubforpmq

In just a few minutes, you'll learn how to search for trials.

Smouldering myeloma is an early form of myeloma that usually progresses over time.
Because it's often asymptomatic, it's typically discovered by chance through blood tests. So it's important to get regular blood tests!

https://f.mtr.cool/dvxpwtgdsl

#MyelomaMonday

#MyelomaMonday - Approximately 10–15% of myeloma patients will develop AL amyloidosis.

Find out more in our guide to AL amyloidosis www.mpeurope.org/wp-content/uploads/2023/...